| 1 | SUPPLEMENTAL MATERIAL | | | | | | | | |
|---------|--|---------------|----------------------------------|-------------------------------|-------------------------------------|------------------------------|------------------------------|------------------------------|--|
| 2 | Title: Role of PATJ in Stroke Prognosis by modulating Endothelial to Mesenchymal | | | | | | | | |
| 3 | Title: R | lol | e of | 'PA' | TJ i | n St | rok | e Pı | rognosis by modulating Endothelial to Mesenchymal |
| 4 5 | 1. SUPP | L | EMI | ENT | ARY | Y TA | BL | ES (| & FIGURES |
| 6 | | | | | | | | | essed genes (FDR P-value ≤ 0.05) between CTL and PATJ |
| 7 | KD cells | s w | ith l | Log2 | fold | l-cha | inge | ≤ 0 .4 | 4 (A) and ≥ 0.4 (B). |
| 8 | SYMBO | DL | logFC -4,95 | AveExpr 9,15 | t -17,59 | P.Value 0,00 | adj.P.Val 0,00 | B 8,65 | GENENAME Integral membrane protein 2A |
| 9 10 | MGP AK5 WASF3 MIR99 | | -4,20 -4,08 -4,03 -3,27 | 6,80 7,16 7,10 9,29 | -17,22 -8,46 -10,31 -13,62 | 0,00 0,00 0,00 0,00 | 0,00 0,01 0,00 0,00 | 8,53 3,67 5,14 7,08 | matrix dia protein aderylate kinason WKS protein family, member 3 mir/d9a.4rt 2 cute hot gane |
| 10 | FOXG1 HOXC1 HOXC2 | 10 | -3,13 -3,12 -3,01 | 9,29 8,08 5,74 6,96 | -13,62 -5,80 -16,92 -13,79 | 0,00 0,00 0,00 | 0,05 0,00 0,00 | 0,86 8,43 7,17 | Init age with a Colour must get the formation of the Colour must get the Colour must g |
| 11 | FRMPD OSBPLI RUNX3 | 6 | -3,00 -2,94 -2,92 | 5,15 5,90 7,13 | -21,00 -14,60 -15,25 | 0,00 0,00 0,00 | 0,00 0,00 0,00 | 9,58 7,54 7,81 | FBM and PD2 domin containing 4 oxysteral binding protein-illia 6 runt reliaded transpirolin factor 3 |
| | ROBO1 BMP6 SULT18 TNIK | | -2,89 -2,89 -2,88 -2,81 | 5,72 7,03 6,00 5,65 | -15,05 -9,84 -14,54 -16,43 | 0,00 0,00 0,00 0,00 | 0,00 0,00 0,00 0,00 | 7,73 4,80 7,51 8,26 | roundbouk puidner erceptor 1 bone morshopemic protein 6 sulforanderase family El ernember 1 TAR2 and NCL: met Ernig kinase |
| 12 | GFRA1 HOXC8 BICC1 | | -2,77 -2,52 -2,33 | 7,44 6,74 6,76 | -9,27 -12,67 -9,45 | 0,00 0,00 0,00 | 0,00 0,00 0,00 | 4,36 6,60 4,50 | GGMF family receptor alphs 1 homeolox C8 BicC family RMs binding protein 1 |
| | CA2 ID1 SLITRK PDE10. | | -2,31 -2,28 -2,20 -2,12 | 6,73 8,53 6,50 6,40 | -13,52 -8,74 -9,77 -17,50 | 0,00 0,00 0,00 0,00 | 0,00 0,00 0,00 0,00 | 7,03 3,91 4,75 8,63 | carbonic anhydraell Inhibitor of RDA Mingling 1. dominant negative helis-loop-helis protein SUT and RDR-like family, member 4 Phospholisterses IDA |
| 13 | SYT15 FGL2 LIMCH | | -2,12 -2,09 -2,08 -2,03 | 5,40 7,92 7,06 5,68 | -17,50 -9,42 -10,59 -15,53 | 0,00 0,00 0,00 | 0,00 0,00 0,00 | 8,63 4,48 5,33 7,92 | programministerio July synaptotagemini kika U.M.and calgonin homology domains 1 |
| | TEX15 FARP1 ZFHX4 | | -1,92 -1,83 -1,78 | 4,90 8,26 7,30 | -15,70 -8,91 -7,70 | 0,00 0,00 0,00 | 0,00 0,00 0,01 | 7,99 4,06 2,96 | tetti sepresed 15 FEMA AHH/MhoGEF and pleckstrin domain protein 1 zinci finger homebox 4 |
| 14 | SOX2 BGN SFRP1 HOXC6 | | -1,74 -1,62 -1,61 -1,57 | 6,86 10,76 5,99 6,02 | -11,09 -18,53 -5,60 -9,03 | 0,00 0,00 0,00 | 0,00 0,00 0,05 0,00 | 5,66 8,94 0,62 4,16 | SHYbox 2 bighran acretaf hiridaf-alatag protein 1 hommobox C6 |
| 45 | TMOD: PHGDF SEMA3 | 1 H | -1,56 -1,51 -1,50 | 7,25 6,97 4,82 | -7,26 -11,97 -8,07 | 0,00 0,00 0,00 | 0,01 0,00 0,01 | 2,52 6,20 3,31 | nomovodk ski tropomodulni z phosphadomár, immunoglobulini domain (gl. short basic domain, secreted, (semaphorin) 31 |
| 15 | SYT15 TRO KCNIP1 | | -1,41 -1,40 -1,36 | 7,96 4,30 5,09 | -6,97 -8,73 -14,48 | 0,00 0,00 0,00 | 0,02 0,00 0,00 | 2,22 3,90 7,48 | Hono supions synaptotagmin XV (SYT15), transcript variant a, mRNA, trophinin Ko-channel intestring protein 1 |
| 16 | TAF7L ADORA PAK3 WNT2E | | -1,35 -1,35 -1,28 -1,17 | 5,31 7,31 5,45 6,91 | -11,25 -7,21 -6,65 -6,15 | 0,00 0,00 0,00 0,00 | 0,00 0,01 0,02 0,04 | 5,77 2,47 1,87 1,29 | TATAba bi inding protein associated fector 7 like demosine AL receptor P23 protein (Cdie2)Zhac)-sectivade tinana 3 wrights kryte MWN (intragration site lank), member 28 |
| 10 | CGNL1 MEIS1 LIMA1 | | -1,16 -1,15 -1,14 | 5,21 7,71 10,15 | -8,22 -8,87 -9,55 | 0,00 0,00 0,00 | 0,01 0,00 0,00 | 3,45 4,02 4,57 | cingulin like 1 Meishomodox 1 UM domain and acts thi briding 1 |
| 17 | AR SEMA3 PCDH1 RPGR | | -1,14 -1,12 -1,08 | 6,29 5,31 7,50 | -6,49 -5,80 -9,21 | 0,00 0,00 0,00 | 0,03 0,05 0,00 | 1,69 0,86 4,30 | androgen receptor terna domain, immunoglobulin domain (glj, short basic domain, secreted, (semaphorin) 30 protocadherin 1 |
| | RPGR PREX2 PFN2 FHOD3 | | -1,05 -1,05 -1,00 -0,97 | 8,98 5,45 9,76 6,98 | -8,58 -7,85 -5,62 -8,02 | 0,00 0,00 0,00 0,00 | 0,01 0,01 0,05 0,01 | 3,78 3,11 0,64 3,27 | relinits jopimentosa Of2ez engular honophatidijimisaria. J.a., Scriptophaphatidi ensista J.a., Scriptophaphatidi ensista J.a., Scriptophatidi ensista profilin 2 formin honologicg 2 domain containing 3 |
| 18 | ANKRD TSPAN: DCH51 | 18 | -0,97 -0,95 -0,95 | 6,59 6,83 5,33 | -7,59 -7,02 -6,77 | 0,00 0,00 0,00 | 0,01 0,02 0,02 | 2,85 2,27 2,00 | ankyrin repat domain 50 tetrapanin 18 dachsous calemini re raited 1 |
| | CDH3 FHDC1 ALDH1 FAM21 | A1 | -0,95 -0,94 -0,91 -0,90 | 7,57 5,36 5,14 5,66 | -6,17 -6,05 -7,08 -7,35 | 0,00 0,00 0,00 0,00 | 0,03 0,04 0,02 0,01 | 1,31 1,18 2,34 2,61 | cadheira's type 1, F-adheira (piakentai) F12 domain containing 1 aldehyde dehydroganasa 1 famiy, member A1 family ukti suqueuse aimiatriy 213, member A |
| 19 | SLITRK LPAR6 SYNE2 | 5 | -0,90 -0,89 -0,88 -0,85 | 5,70 9,60 8,46 | -7,33 -10,11 -5,95 -6,47 | 0,00 0,00 0,00 | 0,00 0,04 0,03 | 4,99 1,06 1,67 | ram y win sątuenie zmieniery z 4,6 mmiero A U Trank MTR-Mielenimi, member 5 lysphosphatidie zad receptor 6 spęctriń nepast containing, nuclear www.loge 2 |
| | SCG5 CHD3 RP11-3 ARHGA | | -0,84 -0,83 -0,83 -0.82 | 6,06 8,04 8,81 5.88 | -6,09 -6,45 -5,60 | 0,00 0,00 0,00 0,00 | 0,04 0,03 0,05 0.01 | 1,22 1,65 0,62 | secretaryanin V chromodomain belicase DNA binding protein 3 |
| 20 | CD109 FAM10 ORFPR |) 01B | -0,82 -0,82 -0,82 -0.82 | 5,88 7,51 7,37 6,53 | -7,49 -6,54 -6,25 -6.08 | 0,00 0,00 0,00 | 0,01 0,03 0,03 0,04 | 2,76 1,74 1,41 1,21 | Nho GTIvaa exituating portain 6 CD199 milectua family with aequence aimiliarity 101, member 8 proyrdiurahude dat Minde potti de receptor |
| 21 | PCDH9 CBLN2 ERRF11 | | -0,79 -0,78 -0,77 | 6,36 5,31 10,97 | -10,55 -7,05 -9,16 | 0,00 0,00 0,00 | 0,00 0,02 0,00 | 5,31 2,30 4,26 | protocatherin 9 cerebelling Zprocursor ERBB receptor Redisackinhibitor 1 |
| 21 | GLDC TMCC3 RNF15 ZNF81/ | 0 | -0,77 -0,77 -0,75 -0.75 | 6,83 6,10 5,07 7.89 | -8,22 -7,50 -8,49 -6.44 | 0,00 0,00 0,00 | 0,01 0,01 0,01 0.03 | 3,45 2,77 3,70 1,63 | glycine deydrogensus (Beschovlating) transmehrane an Golde coil domini family 3 ring finger protein 1.50 ring finger protein 1.50 |
| 22 | ZNF3. ZNF7.1 CXADR PTPRM | 8 | -0,74 -0,72 -0,71 | 6,97 6,67 9,97 | -7,73 -5,71 -6,35 | 0,00 0,00 0,00 | 0,01 0,05 0,03 | 2,99 0,76 1,53 | anis, minger proteins is a constructive virus and ademovirus receptor protein is proving indepotataue, receptor type, M |
| | CDH4 MPP6 RNASE | 1 | -0,70 -0,69 -0,69 | 5,51 8,60 5,91 | -6,06 -5,83 -5,77 | 0,00 0,00 0,00 | 0,04 0,05 0,05 | 1,19 0,90 0,83 | catherin 4, Syea J. R. catherin (retinal) membrane protein, patheringtated 6 forboarciese, Missan Asmity, L gancreatic) |
| 23 | TBX18 PKIB NNMT SPARCI | | -0,68 -0,67 -0,64 -0,64 | 6,15 4,97 11,34 5,02 | -7,13 -5,74 -7,58 -5,77 | 0,00 0,00 0,00 0,00 | 0,01 0,05 0,01 0,05 | 2,39 0,80 2,85 0,83 | Teos 18 protein kinaa (AMP-dependent, catalytic) inhibitor beta nicoti.namide H.methyltrandersae SAAC (like 1 |
| | FAM19 IFNGR3 RBM53 | 95B 1 8 | -0,60 -0,56 -0,56 | 9,23 9,14 10,13 | -7,13 -7,82 -5,66 | 0,00 0,00 0,00 | 0,01 0,01 0,05 | 2,38 3,08 0,69 | family with sequence similarity 195, member 8 interferon gamma receptor 1 ANA binding molt, give paraded interacting protein 3 |
| 24 | SEC14U BPGM CCL27 MSRA | | -0,54 -0,53 0,45 0,45 | 6,73 8,87 7,25 8,60 | -5,58 -5,72 6,37 6,35 | 0,00 0,00 0,00 0,00 | 0,05 0,05 0,03 0,03 | 0,59 0,76 1,55 1,52 | SECI-4 Hie lipid briding 2 2.3-biolphosphogherant emutane chemoking FCC-motif () Igand 27 melhooinse gridicate enductana A |
| | LINCOC OXCT1 ACYP2 | | 0,54 0,57 0,61 | 6,62 9,63 9,60 | 5,98 5,85 8,21 | 0,00 0,00 0,00 | 0,04 0,05 0,01 | 1,09 0,93 3,45 | Inscitioning Announce National National State St |
| 25 | DUSP1 C10orf AHR | | 0,61 0,62 0,65 | 6,64 7,45 10,88 | 5,77 5,72 7,16 | 0,00 0,00 0,00 | 0,05 0,05 0,01 | 0,82 0,77 2,42 | dual specificity phosphatea 15 m chromosome 10 open reading frame 25 any hydrosarbon reagtor |
| 26 | QDPR PTGFR TRPM2 LGALSL | 2 | 0,65 0,65 0,66 0,67 | 7,74 5,52 7,70 9,12 | 7,14 5,73 5,78 8,05 | 0,00 0,00 0,00 0,00 | 0,01 0,05 0,05 0,01 | 2,39 0,78 0,85 3,30 | quinoid dihydroptetidior reductae prostagliand Frequetor (P) translerr receptor potenti al cation channi, wbfamily M, member 2 letrin, galactadie shinding sike |
| 26 | GABBR ARHGE TSACC | 11 1F35 | 0,70 0,70 0,74 | 8,48 8,46 7,34 | 6,46 5,75 5,72 | 0,00 0,00 0,00 | 0,03 0,05 0,05 | 1,65 0,81 0,76 | gamma minobutyric sidi (GAAA) ii receptor, 1 Rho guanina nucleotida exchange factor 3 5 TSSK 6 stivitariji occhaperone |
| 27 | DUSP1 DUSP1 APLF | 16 16 | 0,81 0,83 0,85 | 8,91 7,62 7,44 | 5,66 6,14 6,77 | 0,00 0,00 0,00 | 0,05 0,04 0,02 | 0,69 1,28 2,00 | dual specificity phosphatas 16 dual specificity phosphatas 15 dual specificity phosphatas 15 apratas nad PNRP like factor |
| - 1 | NEU1 GREM1 OCLN C7orf3 | 1 | 0,86 0,88 0,92 0,96 | 9,51 7,32 8,61 7,61 | 7,24 5,79 8,17 6,20 | 0,00 0,00 0,00 0,00 | 0,01 0,05 0,01 0,03 | 2,51 0,86 3,41 1,35 | slalidaef (1 popond slalidae) gemini, 1,0 Menu 1990 Mentagool (Bource HGNC Symbol/AccHGNC 2001) occluini chromosome 7 open reading fame 31 |
| 28 | PDZD2 NIPAL2 SERINC | 2 | 0,99 1,01 1,04 | 8,11 7,74 9,22 | 13,59 6,10 7,75 | 0,00 0,00 0,00 | 0,00 0,04 0,01 | 7,07 1,23 3,01 | PD2 domain containing 2 NBPAllee domain containing 2 serien incorporato 2 |
| | PDE4D TMEMI GPAT2 LURAP | 171 | 1,09 1,21 1,31 1,32 | 7,58 10,06 7,68 4,91 | 10,06 6,06 8,85 8,88 | 0,00 0,00 0,00 0,00 | 0,00 0,04 0,00 0,00 | 4,96 1,19 4,01 4,03 | phophofieldisteriae4 Distancting protein transmitherane protein 171 g/ycrol-3-phophata acytrandramaz, mitochondrial laccine richt akgrego protein 1/ike |
| 29 | NAP1L CYP4V MID2 | .5 2 | 1,39 1,43 1,59 | 7,35 5,70 6,75 | 10,46 9,35 13,80 | 0,00 0,00 0,00 | 0,00 0,00 0,00 | 5,24 4,42 7,17 | nucłosome zusambły protein 1-like 5 cytochrome P450, family 4, subfamily V, polyseptide 2 midline 2 |
| | OSBPL: ELOVL7 LIPH RASGR | 7 | 1,62 1,84 1,99 2,00 | 7,15 6,08 7,22 6,37 | 5,59 8,32 18,04 5,72 | 0,00 0,00 0,00 0,00 | 0,05 0,01 0,00 0,05 | 0,60 3,55 8,80 0,76 | oxystero binding protein like IA LEO/L fetty ad longen 7 lipze, member H MSS pawyl releasing protein 3 (zalcium and DAG-regulated) |
| 30 | NOSTR | | 2,00 | 6,90 | 5,72 10,02 | 0,00 | 0,05 | 0,76 4,93 | NOs guary reesang proten 3 (acrow and DAG-regulated) nitric colle-synthae trafficling |

- 31 Suppl. Table 2. Over-Representation Analysis (ORA) of functional categories with an
- 32 FDR-cut off of 0.05 obtained using WikiPathways.


| | ID | Description | GeneRatio | BgRatio | pvalue | p.adjust | qvalue |
|------------------|------------------|---|----------------------|----------------------|----------------------------|---------------------------|---------------------|
| WP1984 | WP1984 | Integrated breast cancer pathway | 151/6764 | 155/7856 | 1,3267E-06 | 0,000388256 | 0,0002876 |
| WP3888 | WP3888 | VEGFA-VEGFR2 signaling pathway | 409/6764 | 439/7856 | 1,35281E-06 | 0,000388256 | 0,0002876 |
| WP437 | WP437 | EGF/EGFR signaling pathway | 159/6764 | 164/7856 | 2,30651E-06 | 0,000441313 | 0,00032695 |
| WP366 | WP366 | TGF-beta signaling pathway | 130/6764 | 133/7856 | 3,7121E-06 | 0,000532687 | 0,00039465 |
| WP3932 | WP3932 | Focal adhesion: PI3K-Akt-mTOR-signaling pathway | 290/6764 | 309/7856 | 8,36393E-06 | 0,000960179 | 0,0007113 |
| WP5124 | WP5124 | Alzheimer's disease | 254/6764 | 270/7856 | 1,7966E-05 | 0,001489378 | 0,0011034 |
| WP382 | WP382 | MAPK signaling pathway | 235/6764 | 249/7856 | 1,81631E-05 | 0,001489378 | 0,0011034 |
| WP236 | WP236 | Adipogenesis | 127/6764 | 131/7856 | 2,67026E-05 | 0,00170503 | 0,0012632 |
| WP306 | WP306 | Focal adhesion | 192/6764 | 202/7856 | 2,67339E-05 | 0,00170503 | 0,0012632 |
| WP2064 | WP2064 | Neural crest differentiation | 100/6764 | 102/7856 | 3,28646E-05 | 0,001886427 | 0,001397 |
| WP4806 | WP4806 | EGFR tyrosine kinase inhibitor resistance | 83/6764 | 84/7856 | 4,75356E-05 | 0,002480496 | 0,0018377 |
| WP481 | WP481 | Insulin signaling | 154/6764 | 161/7856 | 5,71858E-05 | 0,002735386 | 0,0020265 |
| WP45 | WP45 | G1 to S cell cycle control | 64/6764 | 64/7856 | 6,63801E-05 | 0,002930937 | 0,0021714 |
| WP179 | WP179 | Cell cycle | 118/6764 | 122/7856 | 7,96663E-05 | 0,003169756 | 0,0023483 |
| WP2853 | WP2853 | Endoderm differentiation | 140/6764 | 146/7856 | 8,28333E-05 | 0,003169756 | 0,0023483 |
| WP231 | WP231 | TNF-alpha signaling pathway | 92/6764 | 94/7856 | 9,46153E-05 | 0,003394324 | 0,0025147 |
| WP4787 | WP4787 | Osteoblast differentiation and related diseases | 116/6764 | 120/7856 | 0,000101286 | 0,003419893 | 0,0025337 |
| WP4754 | WP4754 | IL-18 signaling pathway | 260/6764 | 279/7856 | 0,000119551 | 0,003705214 | 0,0027451 |
| WP4239 | WP4239 | Epithelial to mesenchymal transition in colorectal cancer | 157/6764 | 165/7856 | 0,000125627 | 0,003705214 | 0,0027451 |
| WP4172 | WP4172 | PI3K-Akt signaling pathway | 319/6764 | 345/7856 | 0,000129102 | 0,003705214 | 0,0027451 |
| WP2037 | WP2037 | Prolactin signaling pathway | 75/6764 | 76/7856 | 0,000145173 | 0,003968075 | 0,0029398 |
| WP51 | WP51 | Regulation of actin cytoskeleton | 144/6764 | 151/7856 | 0,000169151 | 0,00441331 | 0,0032697 |
| WP4659 | WP4659 | Gastrin signaling pathway | 110/6764 | 114/7856 | 0,000206773 | 0,004955879 | 0,0036716 |
| WP2446 | WP2446 | Retinoblastoma gene in cancer | 86/6764 | 88/7856 | 0,000207214 | 0,004955879 | 0,0036716 |
| WP5087 | WP5087 | Malignant pleural mesothelioma | 393/6764 | 429/7856 | 0,000223395 | 0,005108703 | 0,0037849 |
| WP3584 | WP3584 | MECP2 and associated Rett syndrome | 71/6764 | 72/7856 | 0,0002527 | 0,005108703 | 0,0037849 |
| WP4255 | WP4255 | Non-small cell lung cancer | 71/6764 | 72/7856 | 0,0002527 | 0,005108703 | 0,0037849 |
| WP2018 | WP2018 | RANKL/RANK signaling pathway | 55/6764 | 55/7856 | 0,000258105 | 0,005108703 | 0,0037849 |
| WP2272 | WP2272 | Pathogenic Escherichia coli infection | 55/6764 | 55/7856 | 0,000258105 | 0,005108703 | 0,0037849 |
| WP23 | WP23 | B cell receptor signaling pathway | 95/6764 | 98/7856 | 0,000313492 | 0,005998154 | 0,0044438 |
| WP2380 | WP2380 | Brain-derived neurotrophic factor (BDNF) signaling pathway | 137/6764 | 144/7856 | 0,000354994 | 0,006573113 | 0,0048698 |
| WP3303 | WP3303 | RAC1/PAK1/p38/MMP2 pathway | 68/6764 | 69/7856 | 0,000382215 | 0,006678091 | 0,0049476 |
| WP4666 | WP4666 | Hepatitis B infection | 146/6764 | 154/7856 | 0,000390889 | 0,006678091 | 0,0049476 |
| WP2261 | WP2261 | Glioblastoma signaling pathways | 81/6764 | 83/7856 | 0,000395566 | 0,006678091 | 0,0049476 |
| WP4685 | | Melanoma | 67/6764 | 68/7856 | 0,000438571 | 0,007192558 | 0,0053287 |
| WP4262 | | Breast cancer pathway | 148/6764 | 157/7856 | 0,000828657 | 0,01321247 | 0,0097888 |
| WP4155 | | Endometrial cancer | 62/6764 | 63/7856 | 0,000869629 | 0,013491001 | 0,0099951 |
| WP4263 | | Pancreatic adenocarcinoma pathway | 86/6764 | 89/7856 | 0,000931704 | 0,014073628 | 0,0104268 |
| | WP2034 | Leptin signaling pathway | 74/6764 | 76/7856 | 0,000966759 | 0,014228715 | 0,0105417 |
| | WP5072 | Modulators of TCR signaling and T cell activation | 60/6764 | 61/7856 | 0,001141749 | 0,016384098 | 0,0121385 |
| | WP4217 | Ebola virus pathway in host | 125/6764 | 132/7856 | 0,001217583 | 0,016613469 | 0,012308 |
| WP4946 | WP4946 | DNA repair pathways, full network | 115/6764 | 121/7856 | 0,001242312 | 0,016613469 | 0,012308 |
| WP4216 | | Chromosomal and microsatellite instability in colorectal cancer | 72/6764 | 74/7856 | 0,001244563 | 0,016613469 | 0,012308 |
| WP5053 | | Development of ureteric collection system | 59/6764 | 60/7856 | 0,001244505 | 0,016614613 | 0,0123093 |
| WP4658 | | Small cell lung cancer | 94/6764 | 98/7856 | 0,001312516 | 0,016614613 | 0,0123093 |
| WP254 | WP254 | Apoptosis | 83/6764 | 86/7856 | 0,001312510 | 0,016614613 | 0,0123093 |
| | | | | | | , | |
| | WP4352 WP4321 | Ciliary landscape | 204/6764 | 220/7856 108/7856 | 0,001439293 0,001527809 | 0,017577749 | 0,0130229 |
| | WP4321 WP3931 | Thermogenesis | 103/6764 | | 0,001527809 | 0,017903461 | |
| WP3931 WP4396 | WP3931 WP4396 | Embryonic stem cell pluripotency pathways | 113/6764 150/6764 | 119/7856 160/7856 | 0,001528344 0,001630571 | 0,017903461 | 0,0132642 0,0138684 |
| | WP4396 WP2036 | Nonalcoholic fatty liver disease | , | | 0,001630571 0,001829682 | 0,018718953 0,02019687 | |
| WP2036 | | TNF-related weak inducer of apoptosis (TWEAK) signaling pathway | 42/6764 | 42/7856 | | | 0,0149633 |
| WP466 | WP466 | DNA replication | 42/6764 | 42/7856 | 0,001829682 | 0,02019687 | -, |
| WP2359 | WP2359 WP2355 | Parkin-ubiquitin proteasomal system pathway | 68/6764 | 70/7856 | 0,00205433 | 0,022248781 | 0,0164836 |
| WP2355 | | Corticotropin-releasing hormone signaling pathway | 89/6764 | 93/7856 | 0,002294393 | 0,024388544 | 0,0180689 |
| WP3937 | | Microglia pathogen phagocytosis pathway | 40/6764 | 40/7856 | 0,002472283 | 0,025801648 | 0,0191158 |
| WP395 | WP395 | IL-4 signaling pathway | 54/6764 | 55/7856 | 0,002568358 | | 0,0191843 |
| | WP5115 | Network map of SARS-CoV-2 signaling pathway | 205/6764 | 222/7856 | | 0,025894157 | 0,0191843 |
| WP138 | WP138 | Androgen receptor signaling pathway | 87/6764 | 91/7856 | | 0,027829079 | |
| WP69 | WP69 | T-cell receptor (TCR) signaling pathway | 87/6764 | 91/7856 | | 0,027829079 | |
| WP411 | WP411 | mRNA processing | | 133/7856 | | 0,029087079 | |
| WP536 | WP536 | Calcium regulation in cardiac cells | 142/6764 | 152/7856 | | 0,031375323 | |
| | | Joubert syndrome | 74/6764 | 77/7856 | | 0,035236687 | |
| WP3614 | WP3614 | Photodynamic therapy-induced HIF-1 survival signaling | 37/6764 | 37/7856 | 0,003882529 | 0,035374149 | 0,0262078 |
| WP4018 | WP4018 | Clear cell renal cell carcinoma pathways | 83/6764 | 87/7856 | 0,004422628 | 0,039665442 | 0,0293871 |
| WP289 | WP289 | Myometrial relaxation and contraction pathways | 147/6764 | 158/7856 | 0,004598611 | 0,040331041 | 0,0298803 |
| WP615 | WP615 | Senescence and autophagy in cancer | 102/6764 | 108/7856 | 0,004637367 | 0,040331041 | 0,0298803 |
| WP61 | WP61 | Notch signaling pathway (Netpath) | 61/6764 | 63/7856 | 0,004867962 | 0,041704631 | 0,0308979 |
| | | | 144/6764 | 155/7956 | 0,005905013 | 0,04947375 | 0.0366530 |
| WP5094 | WP5094 | Orexin receptor pathway | 144/0/04 | 155/7856 | 0,003903013 | 0,04947575 | 0,0366539 |

34 Suppl. Table 3. Most significant pathways (Adjusted P-val <0,05) modulated due to

PATJ KD identified through Reactome.


| | Total | Upregulated | Downregulated | | |
|--|-----------------|-------------------------------------|---|--------------|----------|
| Pathway | modulated genes | Genes | Genes2 | Significance | p-value |
| Ectoderm differentiation | 9 | CCL2.TRPM2.EDA2R | FZD4,GRAMD1B,ZFHX4,PTPRB,SKIL,SOX2 | 3.15 | 0.000716 |
| G protein signaling pathways | 7 | PRKAR1B, PDE4A, PDE1B, AKAP3, PRKD1 | PDE4B.GNG4 | 3,02 | 0,000959 |
| Photodynamic therapy-induced unfolded protein response | 4 | DDIT3.NARS.ATF3 | SULT1E1 | 2.98 | 0.001041 |
| Ras signaling | 10 | PLCG2,RASGRP3,KSR2 | KDR.RASGRF1.GNG4.RASSF5.PAK3.ETS2.PLCE1 | 2,92 | 0,001209 |
| Transcriptional cascade regulating adipogenesis | 3 | DDIT3 | GATA2,KLF5 | 2,92 | 0,001213 |
| Myometrial relaxation and contraction pathways | 9 | PLCG2.PRKD1.PRKAR1B.ATF3 | PKIB,RGS9,ETS2,PDE4B,GNG4 | 2,86 | 0.001392 |
| Epithelial to mesenchymal transition in colorectal cancer | 9 | OCLN | NRP2,CDKL2,ID1,CLDN5,COL4A5,COL4A6,WNT2B,FZD4 | 2,76 | 0,001731 |
| TGF-beta signaling pathway | 8 | NEDD4L.STAMBPL1.ATF3 | TERT.SKIL.MEE2C.SIK1.ITGA2 | 2,67 | 0,002144 |
| Pre-implantation embryo | 5 | DDIT3,BATF3 | NR3C2,GATA2,SOX2 | 2,49 | 0,003201 |
| VEGFA-VEGFR2 signaling pathway | 16 | PRKD1,CCL2,OCLN,KATNAL2,PDE4DIP | NRP2, MEF2C, S1PR1, TAL1, GATA2, TRAF3IP2, HTRA1, KANK1, CGNL1, MICAL2, TMOD1 | 2,38 | 0,004168 |
| Lung fibrosis | 5 | CCL2.GREM1 | SKILEDN1.TERT | 2,34 | 0.004553 |
| Hair follicle development: cytodifferentiation - part 3 of 3 | 6 | PERP,FST | SFRP1.SOX2.RUNX3.BMP6 | 2,32 | 0,004747 |
| Hippo-Merlin signaling dysregulation | 8 | PRKAR1B | CDH3,CDH4,ITGA2,ITGB8,KDR,PAK3,PPP1R14A | 2,28 | 0,005271 |
| He effect on hepcidin production | 2 | T HIGHLAD | BMP6.ID1 | 2,25 | 0,005673 |
| Sudden infant death syndrome (SIDS) susceptibility pathways | 8 | PRKAR1B, MYB | HES1, MEF2C, RUNX3, GATA2, AR, SOX2 | 2,23 | 0,006016 |
| Glucocorticoid receptor pathway | 5 | CCL2.PRRG4 | PDE48.PLK2.ALOX5AP | 2,15 | 0.007066 |
| Exercise-induced circadian regulation | 4 | HLA-DMA | GSTM3.CLDN5.GFRA1 | 2,06 | 0,008745 |
| Folate-alcohol and cancer pathway hypotheses | 2 | THE COMPT | ALDH1A1,CB5 | 2,02 | 0,00951 |
| Phosphodiesterases in neuronal function | 4 | PDE1B.PDE4A | PDE10A.PDE4B | 1.91 | 0.012324 |
| Burn wound healing | 6 | CCL2.FST.CD248.IL15 | KDR,PECAM1 | 1,87 | 0,013594 |
| TGF-beta receptor signaling | 4 | FST | SMAD6.SKIL.RUNX3 | 1,85 | 0,013983 |
| Mesodermal commitment pathway | 7 | EXT2 | ZEHX4. KLE5. MEIS1. SMAD6. SQX2. FZD4 | 1,79 | 0,016084 |
| Clear cell renal cell carcinoma pathways | 5 | BHLHE41 | KCNU2.PTEN.PHGDH.KDR | 1.79 | 0,016135 |
| White fat cell differentiation | 3 | DDIT3 | KLF5.GATA2 | 1.78 | 0.016597 |
| TGF-beta receptor signaling in skeletal dysplasias | 4 | FST | SMAD6,SKIL,RUNX3 | 1,75 | 0,017709 |
| Purinergic signaling | 3 | P2RX4 | ADORA1.LPAR6 | 1.74 | 0.018033 |
| Development of ureteric collection system | 4 | FST, GREM1 | ROBO1,GFRA1 | 1.7 | 0,019782 |
| PodNet: protein-protein interactions in the podocyte | 11 | OCLN | SMAD6, EFNB1, SULF1, ROBO1, CDH3, PLCE1, ITGA2, KDR, KHDRBS3, COL4A5 | 1.7 | 0,020101 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 3 | DDIT3.CCL2.ATF3 | | 1.61 | 0.024445 |
| Olfactory receptor activity | 1 | OR2B6 | | 1,61 | 0.024551 |
| Endochondral ossification with skeletal dysplasias | 4 | 01200 | BMP6.MEF2C.RUNX3.MGP | 1.59 | 0.025599 |
| Endochondral ossification | 4 | | BMP6,MEF2C,RUNX3,MGP | 1,59 | 0,025599 |
| GPR40 pathway | 2 | PLCG2 | PLCE1 | 1,59 | 0,025946 |
| Melanoma | 4 | MITE | KDR.PREX2.PTEN | 1.53 | 0,029533 |
| miRNA in muscle cell differentiation | 3 | PRKAR1B,PRKD1 | MEF2C | 1,5 | 0,031929 |
| Estrogen metabolism | 2 | ARSD | SULT1E1 | 1.44 | 0.036572 |
| Sulfation biotransformation reaction | 2 | SULT1C2 | SULTIE1 | 1,44 | 0,036572 |
| Mammary gland development pathway - Embryonic development (Stage 1 of 4) | 2 | | SFRP1,TERT | 1,44 | 0,036572 |
| MECP2 and associated Rett syndrome | 4 | FGF5 | MEF2C.FOXG1.PTEN | 1.43 | 0.036843 |
| Vitamin D receptor pathway | 7 | SULT1C2 | CST6.CLMN.CB5.ID1.SFRP1.BMP6 | 1.4 | 0,039435 |
| Prostaglandin synthesis and regulation | 3 | MITE | EDN1,PTGFRN | 1,37 | 0,042771 |
| Embryonic stem cell pluripotency pathways | 5 | FGF5 | FZD4,PTEN,SMAD6,WNT2B | 1.32 | 0,047442 |
| Phosphoinositides metabolism | 3 | PLCG2 | PTEN, PLCE1 | 1,3 | 0,050048 |
| PI3K-Akt signaling pathway | 11 | IL7R.FGF5.MYB | COL4A5.ITGA2.COL4A6.PTEN.ITGB8.KDR.LPAR6.GNG4 | 1.29 | 0.050848 |
| Focal adhesion | 7 | | ITGB8.KDR.ITGA2,PAK3.PTEN.COL4A6.RASGRF1 | 1,28 | 0,052052 |
| Deubiquitination | 2 | STAMBPL1 | PTEN | 1,20 | 0,053199 |
| GDNF/RET signaling axis | 2 | GREM1 | GFRA1 | 1.24 | 0.05724 |
| Extracellular vesicles in the crosstalk of cardiac cells | 2 | GILLIVII | PTEN,ETS2 | 1,24 | 0,05724 |
| Extracemental vencies in the crosstalk of cardiac cells | 4 | | FIEN,EI32 | 1,24 | 0,03724 |


Suppl. Fig. 1. (A) PATJ KD clones generated by infection with lentiviral particles harboring PATJ-shRNA were selected for the 80 kDa PATJ specie. (B) Clones 1, 2 and 3 were selected for further analysis and cell viability and proliferation was assessed with an MTT assay. No significant differences were observed between CTL and PATJ KD cells after 24 hr growth.



43

Suppl. Fig. 2. Summary of Affymetrix Expression Array Results comparing hCMEC/D3 PATJ





- **Suppl. Fig.3:** Principal Component Analysis of the Affymetrix GeneChip Array Clarion S comparing hCMEC/D3 *PATJ* KD vs CTL cells.
- 73

